Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trialsEmmanuel Mignot, Thomas Roth, David Mayleben et al.|The Lancet Neurology|2022Cited by 240
Daridorexant, a New Dual Orexin Receptor Antagonist to Treat Insomnia DisorderYves Dauvilliers, Jan Hedner, David Mayleben et al.|Annals of Neurology|2020Cited by 145
Long-Term Safety and Tolerability of Daridorexant in Patients with Insomnia DisorderDieter Kunz, Stephen Thein, Yves Dauvilliers et al.|CNS Drugs|2022Cited by 99
Efficacy and Safety of Daridorexant in Older and Younger Adults with Insomnia Disorder: A Secondary Analysis of a Randomised Placebo-Controlled TrialIngo Fietze, W. Vaughn McCall, Dalma Seboek Kinter et al.|Drugs & Aging|2022Cited by 55